Defeat MSA Alliance Board of Directors is pleased to report some good news from Alterity Therapeutics on ATH434, a new drug being developed by the company for the treatment of Multiple System Atrophy.
“Alterity is on track to launch the Phase 2 trial of its lead clinical candidate ATH434 by the end of the calendar year. ATH434 is a small molecule drug being developed for Multiple System Atrophy (MSA), a form of atypical parkinsonism where iron plays a key role in pathogenesis by promoting α-synuclein aggregation. The scientific investigation of ATH434, along with the results from the Phase 2 study, will augment the development and optimization of novel compounds expected to emerge from the new patent.”
For the full report from Alterity, visit their press release here
Wonderful.
This adds to our Hope
Will this be available in UK
We don’t know – the company has not informed us yet where the trial centers will be conducted. We recommend registering with our research platform for research updates:
https://defeatmsa.org/research-registry/
When will ATH-434 BECOME AVAILABLE TO USA?
We don’t know. Any study has to be improved by the FDA to conduct a study in the US.